Futility monitoring for randomized clinical trials with non-proportional hazards: An optimal conditional power approach

被引:1
|
作者
Wang, Xiaofei [1 ]
George, Stephen L. [1 ]
机构
[1] Duke Univ, Sch Med, Dept Biostat & Bioinformat, 2424 Erwin Rd,Suite 1102, Durham, NC 27705 USA
关键词
Average hazard ratio; clinical trial design; delayed treatment effect; futility rules; non-proportional hazards; SAMPLE-SIZE; SURVIVAL; DESIGN; TESTS;
D O I
10.1177/17407745231181908
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background Standard futility analyses designed for a proportional hazards setting may have serious drawbacks when non-proportional hazards are present. One important type of non-proportional hazards occurs when the treatment effect is delayed. That is, there is little or no early treatment effect but a substantial later effect. Methods We define optimality criteria for futility analyses in this setting and propose simple search procedures for deriving such rules in practice. Results We demonstrate the advantages of the optimal rules over commonly used rules in reducing the average number of events, the average sample size, or the average study duration under the null hypothesis with minimal power loss under the alternative hypothesis. Conclusion Optimal futility rules can be derived for a non-proportional hazards setting that control the loss of power under the alternative hypothesis while maximizing the gain in early stopping under the null hypothesis.
引用
收藏
页码:603 / 612
页数:10
相关论文
共 45 条
  • [21] Causal proportional hazards models and time-constant exposure in randomized clinical trials
    Loeys, T
    Goetghebeur, E
    Vandebosch, A
    LIFETIME DATA ANALYSIS, 2005, 11 (04) : 435 - 449
  • [22] Early stopping in clinical trials and epidemiologic studies for "futility": Conditional power versus sequential analysis
    van der Tweel, I
    van Noord, PAH
    JOURNAL OF CLINICAL EPIDEMIOLOGY, 2003, 56 (07) : 610 - 617
  • [23] Causal Proportional Hazards Models and Time-constant Exposure in Randomized Clinical Trials
    T. Loeys
    E. Goetghebeur
    A. Vandebosch
    Lifetime Data Analysis, 2005, 11 : 435 - 449
  • [24] Life expectancy difference and life expectancy ratio: two measures of treatment effects in randomised trials with non-proportional hazards
    Dehbi, Hakim-Moulay
    Royston, Patrick
    Hackshaw, Allan
    BMJ-BRITISH MEDICAL JOURNAL, 2017, 357
  • [25] THE FUTILITY INDEX - AN APPROACH TO THE COST-EFFECTIVE TERMINATION OF RANDOMIZED CLINICAL-TRIALS
    WARE, JH
    MULLER, JE
    BRAUNWALD, E
    AMERICAN JOURNAL OF MEDICINE, 1985, 78 (04): : 635 - 643
  • [26] Clinical effectiveness reporting of novel cancer drugs in the context of non-proportional hazards: a review of nice single technology appraisals
    Salmon, David
    Melendez-Torres, G. J.
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2023, 39 (01)
  • [27] Estimating Treatment Effect in a Proportional Hazards Model in Randomized Clinical Trials with All-or-Nothing Compliance
    Li, Shuli
    Gray, Robert J.
    BIOMETRICS, 2016, 72 (03) : 742 - 750
  • [28] Critical reappraisal of phase III trials with immune checkpoint inhibitors in non-proportional hazards settings (vol 136, pg 159, 2020)
    Castanon, Eduardo
    Sanchez-Arraez, Alvaro
    Alvarez-Mancenido, Felipe
    Jimenez-Fonseca, Paula
    Carmona-Bayonas, Alberto
    EUROPEAN JOURNAL OF CANCER, 2021, 142 : 152 - 153
  • [29] Evaluation of sample size and power for multi-arm survival trials allowing for non-uniform accrual, non-proportional hazards, loss to follow-up and cross-over
    Barthel, F. M. -S.
    Babiker, A.
    Royston, P.
    Parmar, M. K. B.
    STATISTICS IN MEDICINE, 2006, 25 (15) : 2521 - 2542
  • [30] Deviation from the Proportional Hazards Assumption in Randomized Phase 3 Clinical Trials in Oncology: Prevalence, Associated Factors, and Implications
    Rahman, Rifaquat
    Fell, Geoffrey
    Ventz, Steffen
    Arfe, Andrea
    Vanderbeek, Alyssa M.
    Trippa, Lorenzo
    Alexander, Brian M.
    CLINICAL CANCER RESEARCH, 2019, 25 (21) : 6339 - 6345